Now Approved
The first-ever FDA-approved gene therapy for glycogen storage disease type Ia (GSDIa)
Leadership
Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercialization.
Meet our leadership teamPipeline
We have one of the largest and most diverse pipelines in rare disease.
Explore our pipelineGrow with us
We’re growing fast and expanding across functions, including on our Commercial and Medical Affairs teams! Join us to lead the charge in shaping the future of rare disease medicine!
Browse current opportunitiesLatest news
View more news >Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
Rare perspective
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare disease
Read our blog >